Premium
MR targeted imaging for the expression of tenascin‐C in myocardial infarction in vivo
Author(s) -
Song Jiacheng,
Yu Jing,
Li Yan,
Lu Shanshan,
Ma Zhanlong,
Shi Haibin
Publication year - 2017
Publication title -
journal of magnetic resonance imaging
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.563
H-Index - 160
eISSN - 1522-2586
pISSN - 1053-1807
DOI - 10.1002/jmri.25543
Subject(s) - tenascin c , in vivo , myocardial infarction , medicine , infarction , magnetic resonance imaging , tenascin , nuclear medicine , pathology , chemistry , radiology , cell , immunohistochemistry , biology , biochemistry , microbiology and biotechnology , fibronectin
Purpose To investigate the presence of viable myocardium in mice with acute myocardial infarction (MI) using a molecular targeted probe. Materials and Methods Super paramagnetic iron oxide (SPIO) nanoparticles and tenascin‐C antibody were conjugated as an MRI probe. Fifteen mice with infarction were injected with SPIO‐anti‐tenascin‐C (3 days [d], 5d, 7d after infarction; n = 5 for each group). Another five mice with infarction (5d, n = 5) were injected with SPIO for comparison. In vivo MR (7 Tesla, fast low‐angle shot multi‐slice T2* sequence) was performed for tracing. Histological analysis was used to compare surviving cardiomyocytes with signal changes on MR. Results The mRNA expression of tenascin‐C increased directly after MI and peaked at the fifth day (5d 24.29 ± 1.41 versus 3d 10.63 ± 0.72, 7d 6.56 ± 0.12; P < 0.01). T 2 relaxation rate of synthesized SPIO‐anti‐tenascin‐C was r2 = 338 mM −1 s −1 . After MR, the signal changes (contrast‐to‐noise ratio) of the research group were 3d 6.51 ± 1.13 versus 5d 14.06 ± 3.19 versus 7d 5.02 ± 2.65, P < 0.05. The MR signal showed a small decrease in the contrast group on 5d (research group 14.06 ± 3.19 versus contrast group 1.75 ± 0.59, P < 0.05). Conclusion Tenascin‐C was expressed by surviving cardiomyocytes within the infarcted region. MR imaging with SPIO‐anti‐tenascin‐C might be used to evaluate myocardial viability of MI patients before therapy. Level of Evidence : 1 Technical Efficacy : Stage 4 J. MAGN. RESON. IMAGING 2017;45:1668–1674